• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: July 2023

Pharma & Human Health

Treating bladder infections with viruses

July 25, 2023 Microbiome Times

About one in two women are affected by cystitis during her lifetime, and many suffer from recurrent urinary tract infections. Bladder infections are not only painful and potentially dangerous, but they also pose a significant […]

Editor's Choice

Distinguishing Strains in Microbiome Samples: Considerations and Challenges

July 19, 2023 Daniel Quinn

Defining the term “strain” is a conscientious issue within the microbiome field. Broadly speaking, a bacterial strain is a sub-group within a species with unique characteristics such as genetic makeup, metabolism, and morphology. But standards […]

Pharma & Human Health

Ensuring standardised data collection for microbiome research, a sit down with DNA Genotek’s Heloise Breton and Austin Udocor

July 12, 2023 Daniel Quinn

“We want to empower patients and researchers in the microbiome field”, Heloise is passionately describing the applications of DNA Genotek’s FDA-authorised sample collection device “OMNIgene•GUT Dx” to me over zoom. In 2022, the device, which stabilises […]

Finance

Dutch government reserves €200 million for Holomicrobiome Institute

July 5, 2023 Microbiome Times

The Dutch government has reserved €200 million from its National Growth Fund for the establishment of the Holomicrobiome Institute and its activities during the first ten years. The reservation was announced by Minister Adriaansens of […]

Pharma & Human Health

Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation

July 5, 2023 Microbiome Times

The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis. Infants suffering from gastroschisis suffer from risks of growth retardation, sepsis and NEC which leads to increased mortality. Hospital stays for these […]

Finance

Adare Pharma Solutions announces divestiture of postbiotics pioneer Adare Biome to dsm-firmenich

July 4, 2023 Microbiome Times

Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, […]

Finance

Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million

July 3, 2023 Microbiome Times

Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, announced the completion of its €24 million ($26 million) Series A with a last extension […]

Finance

Pendulum Therapeutics Announces Strategic Partnership and $10M Investment from Fonterra

July 3, 2023 Microbiome Times

Pendulum Therapeutics, the biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announced a strategic partnership with New Zealand dairy nutrition company Fonterra. Fonterra will invest $10 million into the growth-stage […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
  • Mental Health and the Brain-Gut-Microbiota Axis: Fundamental Importance of Diet
    April 3, 2025
  • Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation
    March 25, 2025
  • Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis
    March 5, 2025
  • Scientists decode diet from stool DNA – no questions asked
    February 24, 2025
sign up

Sign up to the Microbiome Times newsletter